Survey Questions:

• With PD-1/PD-L1 inhibitors gaining approval for first-line patients across all PD-L1 expression levels, how likely are you to conduct PD- L1 expression testing in the future?
• What proportion of your locally advanced or metastatic NSCLC patients do you currently test for PD-L1 expression?
• Should Opdivo plus Yervoy (ipilimumab; Bristol-Myers Squibb) gain regulatory approval for high-TMB NSCLC patients, how likely are you to conduct both TMB and PD-L1 expression testing?
• How significant will cost be as a factor in deciding whether to conduct both TMB and PD-L1 expression testing?
• For ALK rearrangement-positive and EGFR mutation-positive NSCLC patients, how likely are you to prescribe PD-1/PD-L1 inhibitors in those who have failed previous ALK- or EGFR-targeted tyrosine kinase inhibitors?
• What is your current preferred PD-1/PD-L1 inhibitor in previously treated NSCLC patients?
• Which of the following statements best represents your opinion of vaccine therapies in brain cancer?
• Early-phase data for PD-1 inhibitor Keytruda showed a combined DCR of 23% in docetaxel refractory mCRPC patients regardless of PD- L1 expression. All patients received at least one next-generation endocrine therapy (ie enzalutamide or abiraterone) and one chemotherapy regimen. Grade 3–5 AEs were approximately 12% with Keytruda. If these results hold for larger pivotal studies, what is your view of Keytruda in mCRPC?
• Given the recent clinical trial holds for Keytruda and the discontinuation of Tecentriq’s development in multiple myeloma due to an increase in mortality, do you think there is still a role for PD-1/PD-L1 inhibition in this indication? On a scale of 1 (not likely) to 5 (highly likely), how likely do you think PD-1/PD-L1 inhibitors are to reach the market?
• In your opinion, which immunotherapy combination has the most clinical potential in the treatment of first-line RCC patients?
• Several trials are investigating the potentially synergistic combination of PD-1/PD-L1 and PARP inhibitors in HER2-negative breast cancer. In your opinion, which of these mechanisms is most promising for the treatment of HER2-negative breast cancer patients?
• Which of the following statements best represents your willingness to prescribe patients immunotherapies in indications for which they have been granted accelerated approval?
• What percentage of your patients currently being treated with pharmacological therapy are receiving an immunotherapy? And, in five years, what percentage of your pharmacologically treated patients do you estimate will be receiving an immunotherapy?
• Of all of your patients who are candidates for immunotherapy, what proportion are not able to receive treatment with immunotherapy due to financial reasons (eg out-of-pocket costs of treatment, inadequate insurance coverage, payer preference, etc)?
• In your opinion, which of the following novel immunotherapy mechanisms that were featured in presentations at ASCO 2018 has the most clinical potential?
• Based on the data available so far, do you think combinations featuring IDO inhibitors continue to have a place in development? Please select the statement that best reflects your thoughts on the potential of IDO inhibitors.
• Many presentations surrounding CAR-T therapies at ASCO were focused on fine-tuning their use in the clinical setting. In your opinion, what are the most pressing safety and efficacy priorities that need to be addressed with regards to current CAR-T therapies and those which may enter the market in the near future?